|
|
|
|
| LEADER |
01715nam a2200301 u 4500 |
| 001 |
EB001865478 |
| 003 |
EBX01000000000000001029558 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 100 |
1 |
|
|a Harricharan, Sharada
|
| 245 |
0 |
0 |
|a Guanfacine hydrochloride extended-release for attention deficit hyperactivity disorder
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Sharada Harricharan, Lorna Adcock
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, March 2018
|
| 300 |
|
|
|a 1 PDF file (27 pages)
|
| 653 |
|
|
|a Attention Deficit Disorder with Hyperactivity / drug therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Guanfacine / therapeutic use
|
| 700 |
1 |
|
|a Adcock, Lorna
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK532204
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Since this time, Guanfacine hydrochloride extended-release's (GXR) role in attention-deficit/hyperactivity disorder (ADHD) therapy has continued to be studied. The aim of this review is to assist decision-makers and prescribers by evaluating the recently published evidence on the clinical effectiveness and cost-effectiveness of GXR for the treatment children and adolescents with ADHD. Clinical guidelines will also be examined
|